Chris Hulton

Chris Hulton's work experience begins in 2010 when they worked as an Undergraduate Researcher at The Barnett Institute, Northeastern University. From 2010 to 2011, they also worked as a Research Associate, Formulations at Acceleron Pharma.

In 2011, Chris joined the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, where they worked as a Senior Research Associate, Target Discovery. Their responsibilities included conducting high-throughput genetic screens to identify novel drivers of gastric cancer and validating candidate genes using in vitro cell-based and biochemical assays. They also designed and constructed shRNA and CRISPR/Cas9 plasmid libraries for target validation studies. They remained in this role until 2014.

Starting from 2014, Chris worked as a Graduate Student in the Rudin Lab at Memorial Sloan Kettering Cancer Center until 2019.

In 2019, they joined C4 Therapeutics, Inc. as a Research Scientist I and later promoted to Research Scientist II in 2021. Their tenure at C4 Therapeutics, Inc. lasted until 2022.

Currently, Chris Hulton holds the position of Senior Scientist, Drug Discovery Biology at Treeline Biosciences, which they started in 2022.

Chris Hulton obtained a Bachelor of Science (BS) in Biochemistry from Northeastern University in 2012. Following that, they pursued a Master of Science (MS) in Biotechnology at Northeastern University from 2012 to 2013. Subsequently, they enrolled at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center, where they completed their Doctor of Philosophy (Ph.D.) in Cancer Biology between 2014 and 2019. Prior to their enrollment at Northeastern University, Chris briefly studied Chemistry at Wake Forest University from 2007 to 2009, although no specific degree was obtained during that time.